The drugmaker on Friday said it would make investments in research laboratories and manufacturing sites, mostly geared toward the development of its diabetes treatments, according to the report.
Eli Lilly’s new strategy follows President Donald Trump’s call to bring manufacturing — for drugs and other products — back to the U.S.
CEO David Ricks said he’d make even more investments in the U.S. if the nation offered more favorable tax laws for companies, according to the report.
“The equitable treatment of foreign earnings, a lower U.S. corporate tax rate and U.S. innovation incentives — similar to the rest of the world — will encourage significant investment,” Mr. Ricks told Reuters.
More articles on supply chain:
Viewpoint: Why Americans are too focused on high drug costs
Sen. Sanders eager to partner with Trump on drug cost legislation
4 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
